$38.64
Insights on Ptc Therapeutics, Inc.
Revenue is down for the last 2 quarters, 307.05M → 210.11M (in $), with an average decrease of 31.6% per quarter
Netprofit is up for the last 2 quarters, -155.79M → -91.57M (in $), with an average increase of 70.1% per quarter
In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 92.8%
In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 234.0%
3.04%
Downside
Day's Volatility :3.91%
Upside
0.9%
54.63%
Downside
52 Weeks Volatility :70.66%
Upside
35.33%
Period | Ptc Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 49.19% | -0.6% | 0.0% |
6 Months | 79.69% | 12.1% | 0.0% |
1 Year | -34.26% | 11.3% | 0.0% |
3 Years | -0.79% | 17.6% | -20.1% |
Market Capitalization | 3.0B |
Book Value | - $11.66 |
Earnings Per Share (EPS) | -7.69 |
PEG Ratio | 0.81 |
Wall Street Target Price | 33.64 |
Profit Margin | -62.45% |
Operating Margin TTM | -21.68% |
Return On Assets TTM | -10.29% |
Return On Equity TTM | -7740.12% |
Revenue TTM | 927.6M |
Revenue Per Share TTM | 12.28 |
Quarterly Revenue Growth YOY | -4.7% |
Gross Profit TTM | 2.6M |
EBITDA | -30.6M |
Diluted Eps TTM | -7.69 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.1 |
EPS Estimate Next Year | -3.08 |
EPS Estimate Current Quarter | -1.24 |
EPS Estimate Next Quarter | -1.53 |
What analysts predicted
Downside of 12.94%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 264.7M | ↑ 36.19% |
Net Income | -128.1M | ↑ 62.13% |
Net Profit Margin | -48.38% | ↓ 7.74% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 307.0M | ↑ 15.96% |
Net Income | -251.6M | ↑ 96.42% |
Net Profit Margin | -81.95% | ↓ 33.57% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 380.8M | ↑ 24.04% |
Net Income | -438.2M | ↑ 74.17% |
Net Profit Margin | -115.07% | ↓ 33.12% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 538.6M | ↑ 41.45% |
Net Income | -523.9M | ↑ 19.57% |
Net Profit Margin | -97.27% | ↑ 17.8% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 698.8M | ↑ 29.75% |
Net Income | -559.0M | ↑ 6.7% |
Net Profit Margin | -80.0% | ↑ 17.27% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 937.8M | ↑ 34.2% |
Net Income | -626.6M | ↑ 12.09% |
Net Profit Margin | -66.81% | ↑ 13.19% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 167.4M | ↓ 22.9% |
Net Income | -170.9M | ↑ 56.33% |
Net Profit Margin | -102.08% | ↓ 51.73% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 220.4M | ↑ 31.64% |
Net Income | -139.0M | ↓ 18.68% |
Net Profit Margin | -63.05% | ↑ 39.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 213.8M | ↓ 2.98% |
Net Income | -198.9M | ↑ 43.12% |
Net Profit Margin | -93.02% | ↓ 29.97% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 196.6M | ↓ 8.06% |
Net Income | -133.0M | ↓ 33.14% |
Net Profit Margin | -67.64% | ↑ 25.38% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 307.1M | ↑ 56.2% |
Net Income | -155.8M | ↑ 17.16% |
Net Profit Margin | -50.74% | ↑ 16.9% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 210.1M | ↓ 31.57% |
Net Income | -91.6M | ↓ 41.22% |
Net Profit Margin | -43.58% | ↑ 7.16% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 185.77% |
Total Liabilities | 768.5M | ↑ 226.72% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.6B | ↑ 45.08% |
Total Liabilities | 1.0B | ↑ 33.96% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 2.2B | ↑ 36.0% |
Total Liabilities | 1.7B | ↑ 67.69% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↓ 12.24% |
Total Liabilities | 1.9B | ↑ 12.18% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↓ 11.99% |
Total Liabilities | 2.1B | ↑ 5.99% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↑ 11.58% |
Total Liabilities | 2.7B | ↑ 32.59% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↑ 8.2% |
Total Liabilities | 2.1B | ↑ 13.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.6B | ↓ 5.67% |
Total Liabilities | 2.1B | ↑ 0.67% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 16.83% |
Total Liabilities | 1.9B | ↓ 7.21% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↓ 5.85% |
Total Liabilities | 1.9B | ↑ 0.69% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.9B | ↑ 51.06% |
Total Liabilities | 2.7B | ↑ 40.97% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↓ 5.97% |
Total Liabilities | 2.7B | ↓ 1.4% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -27.6M | ↑ 174.68% |
Investing Cash Flow | -42.6M | ↓ 424.87% |
Financing Cash Flow | 131.6M | ↑ 197.55% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -98.6M | ↑ 256.86% |
Investing Cash Flow | -387.2M | ↑ 808.73% |
Financing Cash Flow | 613.2M | ↑ 366.07% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -194.1M | ↑ 96.75% |
Investing Cash Flow | -561.5M | ↑ 45.01% |
Financing Cash Flow | 668.7M | ↑ 9.05% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -251.3M | ↑ 29.51% |
Investing Cash Flow | 219.2M | ↓ 139.03% |
Financing Cash Flow | 20.9M | ↓ 96.88% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -356.7M | ↑ 41.91% |
Investing Cash Flow | 290.2M | ↑ 32.39% |
Financing Cash Flow | 168.0M | ↑ 704.48% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -166.0M | ↑ 336.23% |
Investing Cash Flow | 32.4M | ↓ 76.23% |
Financing Cash Flow | 302.9M | ↓ 316.38% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -29.5M | ↓ 82.23% |
Investing Cash Flow | -29.0M | ↓ 189.31% |
Financing Cash Flow | 4.1M | ↓ 98.65% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -14.1M | ↓ 52.12% |
Investing Cash Flow | -23.8M | ↓ 18.01% |
Financing Cash Flow | 18.5M | ↑ 350.9% |
Sell
Neutral
Buy
Ptc Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Ptc Therapeutics, Inc. | 49.6% | 79.69% | -34.26% | -0.79% | -3.81% |
Moderna, Inc. | 37.56% | 83.82% | 13.37% | -12.47% | 553.14% |
Regeneron Pharmaceuticals, Inc. | 10.42% | 24.29% | 32.26% | 98.6% | 210.52% |
Novo Nordisk A/s | 7.9% | 30.89% | 58.53% | 230.87% | 458.51% |
Vertex Pharmaceuticals Incorporated | 10.52% | 25.13% | 30.01% | 109.26% | 156.43% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Ptc Therapeutics, Inc. | NA | NA | 0.81 | -5.1 | -77.4 | -0.1 | NA | -11.66 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.46 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 29.16 | 29.16 | 1.46 | 44.2 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 45.83 | 45.83 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 28.9 | 28.9 | 0.53 | 17.11 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Ptc Therapeutics, Inc. | Hold | $3.0B | -3.81% | NA | -62.45% |
Moderna, Inc. | Buy | $54.0B | 553.14% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.8B | 210.52% | 29.16 | 29.45% |
Novo Nordisk A/s | Buy | $592.1B | 458.51% | 45.83 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $115.1B | 156.43% | 28.9 | 39.46% |
Wellington Management Company LLP
Vanguard Group Inc
BlackRock Inc
RTW INVESTMENTS, LLC
Armistice Capital, LLC
State Street Corporation
Ptc Therapeutics, Inc.’s price-to-earnings ratio stands at None
Read Moreptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.
Organization | Ptc Therapeutics, Inc. |
Employees | 988 |
CEO | Dr. Matthew B. Klein F.A.C.S., M.D., M.S. |
Industry | Health Technology |
Enstar Group Ltd
$38.64
-0.54%
Capri Holdings Limited
$38.64
-0.54%
Boston Properties Inc.
$38.64
-0.54%
Capital Group Global Growth
$38.64
-0.54%
Bright Horizons Family Solutions Inc
$38.64
-0.54%
Spdr S&p 400 Mid Cap Value E
$38.64
-0.54%
Cnx Resources Corp.
$38.64
-0.54%
International Seaways, Inc.
$38.64
-0.54%
Janux Therapeutics Inc
$38.64
-0.54%